The Plant-Based Biologics Market involves the production of biologics or biopharmaceuticals using plant systems and plant cell culture techniques as an alternative to bacterial and mammalian cell-based productions. Plant-based biologics production platforms can manufacture complex therapeutic proteins including monoclonal antibodies, peptides, and vaccines at commercial scale with human-compatible post-translational modifications similar to mammalian cell systems but with lower capital and production costs.
Some key advantages of plant-based biologics include the ease of genetic engineering, rapid scalability, lack of animal pathogens, and fewer biofermentation requirements. The growing need for more sustainable and affordable biologics production methods is driving innovation in the plant-based biologics space.
The Global Plant-Based Biologics Market is estimated to be valued at US$ 15.8 Bn in 2024 and is expected to exhibit a CAGR of 8.2% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Plant-Based Biologics Market include DSM Nutritional Products, Lycored, Lycored SARL, FutureCeuticals, Vidya Herbs, Allied Biotech Corporation, Avestia Pharma, Xi’an Green Source Co., Ltd., Beijing Gingko Group (BGG), and Shaanxi Jiahe Phytochem Co., Ltd. Key players are investing in R&D to develop new plant-based production platforms and expand human clinical trials of plant-made biologics products.
The growing Plant-Based Biologics Market Demand for affordable biologic drugs and therapeutics globally is driving increasing interest in plant-based biologics production methods. Once commercialized, plant-based systems could enable production of biologics at a fraction of current bacterial and mammalian cell culture costs. This will allow biologics to be accessible to more patients worldwide.
Major players are also partnering or acquiring small biotech companies working in the plant-based biologics space to expand globally. As human clinical data validates plant-based platforms, large pharmaceutical companies are expected to increasingly adopt this approach to produce pipeline biologics or to supplement existing manufacturing capacity needs.
Market Drivers
One of the key drivers fuelling growth in the plant-based biologics market is the increasing gap between supply and demand for biologic drugs. With rising incidence of chronic diseases globally and rapid approvals of novel biologics, the need for large-scale, cost-effective production methods is growing. Plant-based systems can help bridge this gap by offering higher production capacity compared to other traditional methods. This is expected to significantly bolster the plant-based biologics market over the forecast period.
The current geopolitical instability due to the ongoing Russia-Ukraine war can potentially impact the growth trajectory of the plant-based biologics market. The conflict has disrupted supply chains and inflation has risen sharply across Europe and globally. This can pose challenges to scaling up production and reducing costs in the near term. However, biopharma companies are likely to focus on regionalizing manufacturing and sourcing to address supply vulnerabilities. Governments and private players may also provide incentives to boost local manufacturing and resource security.
The market will see continued growth driven by demand for affordable alternatives to conventional medicine. Plant-based drug production methods have gained acceptance among pharmaceutical regulators. Once supply chain issues are stabilized, production capacities will be augmented to serve markets in Europe, Asia Pacific and North America where demand is dominant currently. Industry-academia collaborations for research on new drug candidates sourced from diverse flora can also aid product development and geographical expansion in the long run.
Geographically, Europe currently accounts for the largest share of the Plant-Based Biologics Market Regional Analysis in terms of value. Major European countries such as Germany, UK, and France have been early adopters and a sizeable number of clinical trials are being conducted in these nations. Concerns around sustainability and animal welfare have boosted research into green alternatives in the region.
The Asia Pacific region, on the other hand, is poised to become the fastest growing regional market during the forecast period. This is attributed to rising R&D investments by biotech firms from India, China and Japan focusing on plant-based drug molecules.
get more insights on plant-based biologics market
Pick the language that you prefer-
About Author-
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice’s dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
